First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.

NCT04535167

Last updated date
Study Location
El Camino Health
Mountain View, California, 94040, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Viral Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female participants between the ages of 18 and 75 years.

2. Confirmed SARS-CoV-2 infection as determined by standard RT- PCR assay.

3. Hospitalized for COVID-19, with mild or moderate disease (8-point ordinal scale categories 4 to 7).

4. Symptoms consistent with mild or moderate COVID-19 indicated by at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath (at rest or with exertion), or dyspnea.

5. Total body weight >=50 kg (110 lb), BMI <35 kg/m2.

-

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Evidence of critical illness, defined by at least one of the following:
Respiratory failure, Multi-organ dysfunction/failure, Cardiac failure or septic
shock


2. Participants with pre-existing moderate to severe cardiovascular disease,
uncontrolled diabetes, or severe asthma or severe COPD.


3. Participants with a known medical history of recent acute or chronic liver
disease (other than NASH), chronic or active hepatitis B or C infection, or
primary biliary cirrhosis.


4. Participants with known HIV infection.


5. Participants with a known medical history of ischemic heart disease, heart
failure, dysrhythmia or other pre-existing cardiac condition.


6. Participants with a known medical history of recurrent seizures.


7. Confirmed concurrent active systemic infection other than COVID-19.


8. Current diagnosis of cancer, unless in remission and untreated.


9. Other medical or psychiatric condition including recent or active suicidal
ideation/behavior or laboratory abnormality that may increase the risk of study
participation


10. Previous administration with any investigational drug (including Remdesivir,
convalescent sera or Monoclonal antibody treatment for COVID-19 if not local
standard of care) within 30 days.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Viral DiseaseFirst-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.
NCT04535167
  1. Mountain View, California
  2. Mountain View, California
  3. Newport Beach, California
  4. Sacramento, California
  5. Sacramento, California
  6. Iowa City, Iowa
  7. Tacoma, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.
Official Title  ICMJE A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND EXTENDED (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH MILD TO MODERATE COVID-19
Brief Summary It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients with SARS-CoV-2 virus infection and with mild-to-moderate symptoms.
Detailed Description

It is a 2-part study in mild to moderate hospitalized COVID-19 patients.

  • Part 1 is to evaluate safety, tolerability, PK and markers of clinical activity of escalating doses of PF-07304814 given as 24-hour IV infusions.

    3 planned and 2 optional cohorts with 8 participants each are planned.

  • Part 2 is to evaluate safety, tolerability, PK and markers of clinical activity with extended 120-hour IV infusion of PF 07304814.

    1. planned and 1 optional cohorts with 8 participants each are planned
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Part 1 will have 3 planned cohorts. Each cohort will be initiated for enrollment after assessment of safety, tolerability and PK data from previous cohorts by an independent IRC and is deemed acceptable.

Part 2 will be initiated after all safety, tolerability and PK data from Part 1 is evaluated and is deemed acceptable.

Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Viral Disease
Intervention  ICMJE
  • Drug: PF-07304814
    PF-07304814 is an anti-viral, formulated for intravenous delivery
  • Drug: Placebo
    Placebo will be formulated for intravenous delivery
Study Arms  ICMJE
  • Experimental: PF-07304814

    Part 1:

    Cohort 1-5

    Part 2:

    Cohort 6,7

    Intervention: Drug: PF-07304814
  • Placebo Comparator: Placebo

    Part 1:

    Cohort 1-5

    Part 2:

    Cohort 6,7

    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 31, 2020)
56
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 21, 2021
Estimated Primary Completion Date March 21, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • Inclusion Criteria:

    1. Male or female participants between the ages of 18 and 75 years.
    2. Confirmed SARS-CoV-2 infection as determined by standard RT- PCR assay.
    3. Hospitalized for COVID-19, with mild or moderate disease (8-point ordinal scale categories 4 to 7).
    4. Symptoms consistent with mild or moderate COVID-19 indicated by at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath (at rest or with exertion), or dyspnea.
    5. Total body weight >=50 kg (110 lb), BMI <35 kg/m2.
  • Exclusion Criteria:

    1. Evidence of critical illness, defined by at least one of the following: Respiratory failure, Multi-organ dysfunction/failure, Cardiac failure or septic shock
    2. Participants with pre-existing moderate to severe cardiovascular disease, uncontrolled diabetes, or severe asthma or severe COPD.
    3. Participants with a known medical history of recent acute or chronic liver disease (other than NASH), chronic or active hepatitis B or C infection, or primary biliary cirrhosis.
    4. Participants with known HIV infection.
    5. Participants with a known medical history of ischemic heart disease, heart failure, dysrhythmia or other pre-existing cardiac condition.
    6. Participants with a known medical history of recurrent seizures.
    7. Confirmed concurrent active systemic infection other than COVID-19.
    8. Current diagnosis of cancer, unless in remission and untreated.
    9. Other medical or psychiatric condition including recent or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
    10. Previous administration with any investigational drug (including Remdesivir, convalescent sera or Monoclonal antibody treatment for COVID-19 if not local standard of care) within 30 days.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04535167
Other Study ID Numbers  ICMJE C4611001
2020-003905-73 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP